ECA
WST icon

Elevated Capital Advisors’s West Pharmaceutical WST Stock Holding History

Elevated Capital Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
730
-677
-48% -$207K 0.07% 227
2026
Q1 		$353K Buy
1,407
+223
+19% +$55.5K 0.09% 207
2025
Q4 		$326K Sell
1,184
-204
-15% -$55.8K 0.08% 229
2025
Q3 		$364K Sell
1,388
-72
-5% -$17.5K 0.09% 225
2025
Q2 		$327K Hold
1,460
– – 0.09% 218
2025
Q1 		$327K Buy
1,460
+65
+5% +$17.9K 0.09% 218
2024
Q4 		$457K Buy
1,395
+94
+7% +$29.6K 0.12% 200
2024
Q3 		$391K Buy
1,301
+105
+9% +$32.2K 0.1% 225
2024
Q2 		$394K Buy
1,196
+163
+16% +$57.6K 0.11% 187
2024
Q1 		$409K Buy
1,033
+62
+6% +$22.9K 0.12% 143
2023
Q4 		$342K Buy
971
+64
+7% +$22.6K 0.11% 151
2023
Q3 		$340K Sell
907
-30
-3% -$11.6K 0.12% 144
2023
Q2 		$358K Buy
937
+20
+2% +$7.14K 0.12% 151
2023
Q1 		$318K Sell
917
-39
-4% -$11.4K 0.11% 148
2022
Q4 		$225K Buy
+956
New +$227K 0.09% 150

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Elevated Capital Advisors's WST Position: Q2 2026 in Review

Elevated Capital Advisors reduced its West Pharmaceutical (WST) stake by 48% in Q2 2026, selling an estimated $207K and leaving 730 shares worth $262K. The position accounts for 0.07% of the portfolio, ranked #227.

Elevated Capital Advisors first reported a position in WST in Q4 2022 and has held it in 15 quarters since. The position peaked at $457K in Q4 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Elevated Capital Advisors held 730 shares of West Pharmaceutical worth $262K as of Q2 2026.
  • Elevated Capital Advisors sold 677 West Pharmaceutical shares in Q2 2026, an estimated $207K.
  • West Pharmaceutical made up 0.07% of Elevated Capital Advisors's portfolio in Q2 2026, its #227 holding.
  • Elevated Capital Advisors first reported a position in West Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • Elevated Capital Advisors's West Pharmaceutical position peaked at $457K in Q4 2024.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.